1. Home
  2. HOV vs NTLA Comparison

HOV vs NTLA Comparison

Compare HOV & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HOV
  • NTLA
  • Stock Information
  • Founded
  • HOV 1959
  • NTLA 2014
  • Country
  • HOV United States
  • NTLA United States
  • Employees
  • HOV N/A
  • NTLA N/A
  • Industry
  • HOV Homebuilding
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • HOV Consumer Discretionary
  • NTLA Health Care
  • Exchange
  • HOV Nasdaq
  • NTLA Nasdaq
  • Market Cap
  • HOV 1.3B
  • NTLA 1.4B
  • IPO Year
  • HOV N/A
  • NTLA 2016
  • Fundamental
  • Price
  • HOV $175.51
  • NTLA $13.80
  • Analyst Decision
  • HOV Hold
  • NTLA Buy
  • Analyst Count
  • HOV 1
  • NTLA 17
  • Target Price
  • HOV $155.00
  • NTLA $56.63
  • AVG Volume (30 Days)
  • HOV 63.6K
  • NTLA 3.1M
  • Earning Date
  • HOV 12-03-2024
  • NTLA 11-07-2024
  • Dividend Yield
  • HOV N/A
  • NTLA N/A
  • EPS Growth
  • HOV 48.22
  • NTLA N/A
  • EPS
  • HOV 31.75
  • NTLA N/A
  • Revenue
  • HOV $2,912,312,000.00
  • NTLA $43,086,000.00
  • Revenue This Year
  • HOV N/A
  • NTLA $50.73
  • Revenue Next Year
  • HOV N/A
  • NTLA $8.69
  • P/E Ratio
  • HOV $5.42
  • NTLA N/A
  • Revenue Growth
  • HOV 5.68
  • NTLA N/A
  • 52 Week Low
  • HOV $86.61
  • NTLA $12.82
  • 52 Week High
  • HOV $240.34
  • NTLA $34.87
  • Technical
  • Relative Strength Index (RSI)
  • HOV 45.94
  • NTLA 36.15
  • Support Level
  • HOV $164.70
  • NTLA $12.82
  • Resistance Level
  • HOV $188.60
  • NTLA $17.30
  • Average True Range (ATR)
  • HOV 8.94
  • NTLA 1.11
  • MACD
  • HOV 0.40
  • NTLA -0.11
  • Stochastic Oscillator
  • HOV 42.73
  • NTLA 19.56

About HOV Hovnanian Enterprises Inc.

Hovnanian Enterprises Inc conducts all of its homebuilding and financial services operations . The company designs, constructs, markets, and sells single-family detached homes, attached townhomes and condominiums, urban infill, and active lifestyle homes in planned residential developments. It has two distinct operations: homebuilding and financial services. Its homebuilding operations are divided geographically into three segments; Northeast which includes Delaware, Maryland, New Jersey, Ohio, Pennsylvania, Virginia and West Virginia; Southeast which includes Florida, Georgia and South Carolina; and West which includes Arizona, California and Texas. The firm generates maximum revenue from West Segment.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: